One surgeon's preference for an ophthalmic viscosurgical device of 1.6% sodium hyaluronate was reinforced by a study that found it superior to another OVD during phaco and OVD removal
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.